These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18184868)

  • 41. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 42. Primary central nervous system lymphomas associated with chronic inflammation: diagnostic pitfalls of central nervous system lymphomas.
    Sugita Y; Masuoka J; Kameda K; Takahashi K; Kimura Y; Higaki K; Furuta T; Ohshima K
    Brain Tumor Pathol; 2020 Oct; 37(4):127-135. PubMed ID: 32627089
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma.
    Bödör C; Alpár D; Marosvári D; Galik B; Rajnai H; Bátai B; Nagy Á; Kajtár B; Burján A; Deák B; Schneider T; Alizadeh H; Matolcsy A; Brandner S; Storhoff J; Chen N; Liu M; Ghali N; Csala I; Bagó AG; Gyenesei A; Reiniger L
    J Neuropathol Exp Neurol; 2020 Feb; 79(2):176-183. PubMed ID: 31886867
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.
    Vater I; Montesinos-Rongen M; Schlesner M; Haake A; Purschke F; Sprute R; Mettenmeyer N; Nazzal I; Nagel I; Gutwein J; Richter J; Buchhalter I; Russell RB; Wiestler OD; Eils R; Deckert M; Siebert R
    Leukemia; 2015 Mar; 29(3):677-85. PubMed ID: 25189415
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
    Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
    Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Absence of Lymphatic Vessels in PCNSL May Contribute to Confinement of Tumor Cells to the Central Nervous System.
    Deckert M; Brunn A; Montesinos-Rongen M; Siebert R
    J Neuropathol Exp Neurol; 2016 Jun; 75(6):499-502. PubMed ID: 27142645
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metallothionein-I + II and receptor megalin are altered in relation to oxidative stress in cerebral lymphomas.
    Pedersen MØ; Hansen PB; Nielsen SL; Penkowa M
    Leuk Lymphoma; 2010 Feb; 51(2):314-28. PubMed ID: 20038220
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selective central nervous system tropism of primary central nervous system lymphoma.
    Jiang L; Marlow LA; Cooper SJ; Roemeling CV; Menke DM; Copland JA; Tun HW
    Int J Clin Exp Pathol; 2010 Oct; 3(8):763-7. PubMed ID: 21151389
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Primary large B-cell lymphoma of the central nervous system with cyclin D1 expression and t(11;14) (IGH-CCND1): Diffuse large B-cell lymphoma with CCND1 rearrangement or mantle cell lymphoma?
    Parrott AM; Haggiagi AM; Murty VV; Bhagat G; Alobeid B
    Hematol Oncol; 2020 Dec; 38(5):817-822. PubMed ID: 32639587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Testicular Relapse of Primary Diffuse Large B-cell Lymphoma of the Central Nervous System - a Rare Occurrence.
    Ollila TA; Kishkovich TP; Olszewski AJ; Patel NR; Jackson C; Roussel B; Niroula R; Treaba DO
    R I Med J (2013); 2023 Mar; 106(2):8-12. PubMed ID: 36848533
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phosphoproteome analysis of cerebrospinal fluid extracellular vesicles in primary central nervous system lymphoma.
    Deng Y; Li Q; Sun J; Ma L; Ding Y; Cai Y; Iliuk A; Chen B; Xie Z; Tao WA
    Analyst; 2023 Jul; 148(15):3594-3602. PubMed ID: 37403840
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary central nervous system lymphoma: advances in its pathogenesis, molecular markers and targeted therapies.
    Hernández-Verdin I; Morales-Martínez A; Hoang-Xuan K; Alentorn A
    Curr Opin Neurol; 2022 Dec; 35(6):779-786. PubMed ID: 36367044
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma.
    Yushi Q; Li Z; Von Roemeling CA; Doeppler H; Marlow LA; Kim BY; Radisky DC; Storz P; Copland JA; Tun HW
    Oncotarget; 2016 May; 7(22):32156-71. PubMed ID: 27050077
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LCK expression is a potential biomarker for distinguishing primary central nervous system lymphoma from glioblastoma multiforme.
    Ge L; Xu L; Lu S; Yan H
    FEBS Open Bio; 2020 May; 10(5):904-911. PubMed ID: 32237064
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanisms of intracerebral lymphoma growth delineated in a syngeneic mouse model of central nervous system lymphoma.
    Montesinos-Rongen M; Sánchez-Ruiz M; Brunn A; Hong K; Bens S; Perales SR; Cigudosa JC; Siebert R; Deckert M
    J Neuropathol Exp Neurol; 2013 Apr; 72(4):325-36. PubMed ID: 23481709
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
    Ollila TA; Olszewski AJ
    Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma.
    Hattori K; Sakata-Yanagimoto M; Kusakabe M; Nanmoku T; Suehara Y; Matsuoka R; Noguchi M; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Muratani M; Hasegawa Y; Chiba S
    Cancer Sci; 2019 Jan; 110(1):401-407. PubMed ID: 30353605
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Primary central nervous system lymphoma: a clinicopathological study of 75 cases.
    Preusser M; Woehrer A; Koperek O; Rottenfusser A; Dieckmann K; Gatterbauer B; Roessler K; Slavc I; Jaeger U; Streubel B; Hainfellner JA; Chott A
    Pathology; 2010; 42(6):547-52. PubMed ID: 20854073
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discrepancy Between Low Levels of mTOR Activity and High Levels of P-S6 in Primary Central Nervous System Lymphoma May Be Explained by PAS Domain-Containing Serine/Threonine-Protein Kinase-Mediated Phosphorylation.
    Marosvári D; Nagy N; Kriston C; Deák B; Hajdu M; Bödör C; Csala I; Bagó AG; Szállási Z; Sebestyén A; Reiniger L
    J Neuropathol Exp Neurol; 2018 Apr; 77(4):268-273. PubMed ID: 29361117
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
    Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
    Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.